Refocus Group, Inc. is a medical device company engaged in the research and development of treatments for human vision disorders. Our mission is to become the surgical standard of care for presbyopia, primary open-angle glaucoma and ocular hypertension worldwide.

Refocus Group's main product is the PresVIEW™ Scleral Implant (PSI), which is used in an innovative procedure known as the the Scleral Spacing Procedure (SSP). The PSI is an investigational device and is not yet approved for sale or use in the United States or Canada.  However, the product is currently approved for sale in the European Union.